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underwent 3.6 distinct medication regimens with each, on
average, having 2 drugs. Poly-pharmacy (multiple drug combi-
nation) treatments represent 60% of the days of treatment and
a disproportionate 82% share of costs. Average paid cost per day
of treatment for those using poly-pharmacy is $7.56, whereas
monotherapy is $2.47. Twenty-three percent of patients are
treated with poly-pharmacy initially and permanently. Anti-
psychotics and benzodiazapine-based treatments are most com-
monly seen (80%) in poly-pharmacy treatments. Increasing
severity of illness is related to increased poly-pharmacy, with the
exception of those patients in remission. CONCLUSION: Phar-
macologic treatment of bipolar is challenging, individualized and
characterized by poly-pharmacy, reﬂecting the cyclical nature of
the disorder. The impact of the complexity of treating bipolar
needs to be studied to determine how service utilization and costs
are inﬂuenced.
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OBJECTIVE: In part because of its cyclical nature, bipolar dis-
order is frequently missed or misdiagnosed in clinical practice.
Over one third of bipolar patients report a period of 10+ years
between initially seeking treatment and proper diagnosis. Under-
standing when and where bipolar disorder is being diagnosed
represents an important step for targeting efforts to improve the
accurate identiﬁcation of bipolar patients. METHODS: To
examine characteristics of initial bipolar diagnosis, the Phar-
Metrics Integrated Outcomes Database of adjudicated medical
and pharmaceutical claims for over 3 million patients from 11
U.S. health plans was utilized. We identiﬁed 3,648 bipolar
patients based on the following criteria: two claims with ICD-9-
CM diagnosis for bipolar disorder (296.0, 296.1, 296.4–296.8)
that were not accompanied by a unipolar depression or schizo-
phrenia claim on the same day, age between 10 and 64, and 1
year of continuous eligibility prior to and following the initial
bipolar diagnosis. RESULTS: Of the 3648 patients, 1859 (51%)
had sufﬁcient diagnostic information to identify the current
phase of the disorder. Of these 1859 patients, 69% were diag-
nosed during either a manic or mixed episode. Most frequently
the diagnostic claim was associated with a mental health spe-
cialist (64%), with only 7% being associated with a family or
general practitioner. The majority of index diagnoses were at
outpatient visits (75%), followed by inpatient hospitals (15%),
and Emergency Rooms (2%). On average, patients incurred
$9241 in paid claims per year, of which $2610 (28%) occurred
in the 2 weeks before and after the bipolar index date. During
this month surrounding initial diagnosis, hospitalizations
accounted for 72% of the costs. CONCLUSIONS: Bipolar dis-
order appears to be most commonly diagnosed at outpatient
visits by mental health specialists when symptoms of mania are
present. Earlier recognition and treatment may reduce the spike
in costs that surrounds the initial diagnosis.
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OBJECTIVE: To examine managed-care prescribing patterns for
patients beginning pharmacologic treatment in the depressive
phase of bipolar. METHODS: This retrospective study
(1995–2002) included a cohort of 1203 patients who had 3 con-
secutive years of data, received an ICD coded diagnosis of
bipolar depression and received one of four classes of psy-
chotropic medication (i.e. antidepressant, antipsychotic, benzo-
diazapine, or mood stabilizer). Treatment patterns were observed
for a one-year period post diagnosis. RESULTS: Seventy-seven
percent of extracted data was between 1999–2002. Fifty-ﬁve dif-
ferent medications were used to create multiple unique mono
and/or combination pharmacologic treatments. Nine percent of
patients began their treatment in accordance with APA guide-
lines, whereas, 16% began treatment using only an antidepres-
sant. As switches in treatment occur, use of mono-therapy
treatments decrease (-12%) and use of four or more medication
combinations increase (+9%). One third of patients were treated
with four or more medications in combination, at some point,
during the year following diagnosis. CONCLUSION: Pharma-
cologic treatment of bipolar depression is characterized by poly-
pharmacy, reﬂecting the complexity of the disorder; and is often
not aligned with guidelines. There is a need to study how these
patterns impact service utilization and costs, as well as to further
understand the treatment patterns.
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OBJECTIVES: To assess the construct validity and reliability of
the Center for Epidemiologic Studies Depression (CES-D) scale
in stroke patients, and to examine item functioning in depressed
stroke patients compared to generalized depression.
METHODS: Psychometric analyses were conducted on sec-
ondary data sources, including 101 patients 3, months post-
stroke (of whom 32 were depressed), and 366 individuals with
depression from the US general population. Presence of (poten-
tial) depression was based on a CES-D score ≥16. Convergent
validity of the CES-D scale in stroke patients was assessed with
concurrently administered measures—the SF-36 mental health
subscale (MH), and the Health Utilities Index Mark 2 and 3
single attribute utility score for emotion (HUI2-E, HUI3-E,
respectively)—using Spearman’s rank correlation coefﬁcients (r).
Internal consistency reliability was assessed using Cronbach’s a.
Rasch analysis was used to compare item hierarchies and to iden-
tify differential item functioning (DIF) between generalized
depression and depression after stroke. RESULTS: The CES-D
was strongly correlated with the MH subscale (r = -0.81), HUI2-
E (r = -0.71) and HUI3-E (r = -0.66). Internal consistency reli-
ability of the CES-D scale in stroke patients was satisfactory
(Cronbach’s a = 0.90). Rasch analysis identiﬁed several items that
were redundant or did not contribute to scale consistency. Item
hierarchies separated into similar strata of difﬁculty for
depressed stroke patients and generalized depression, with inter-
personal disruption items (people unfriendly, feeling disliked)
being the most difﬁcult to endorse in both samples. DIF between
generalized depression and stroke was identiﬁed on items relat-
ing to appetite, restless sleep, crying, and feeling disliked. CON-
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CLUSIONS: Classical test theory-based psychometric methods
generally supported the CES-D scale as an outcome measure of
depression after stroke. DIF on some items suggests that symp-
toms experienced in post-stroke depression may differ from
depression in the general population.
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Clinical trials often employ self-rated and interviewer-rated
instruments to assess the effectiveness of anxiolytic treatments.
Understanding potential differences in these scales and their psy-
chometric properties therefore is important for interpreting trial
results. OBJECTIVES: Identify and critique key methods used to
compare psychometric properties of self-versus interviewer-rated
instruments in clinical trials for patients with anxiety disorders.
METHODS: A literature review focusing on anxiety outcome
assessments used in clinical trials was conducted in Medline,
OLGA, and PsychINFO databases of articles published before
September 2003. This study included only articles that were pub-
lished in English and reported data from clinical trials with anx-
iolytic drugs. RESULTS: From the literature review, two
commonly used instruments included the self-rated Symptom
Checklist-90, and the interviewer-rated Hamilton Rating Scale
for Anxiety. Five methodological approaches were identiﬁed: 1)
precision of measurement: means and variances of instrument
scores; 2) construct validity: comparison of underlying con-
structs for each instrument using factor analysis; 3) internal 
consistency: homogeneity of items within the same domain of an
instrument; 4) instrument sensitivity: ability of the instrument to
detect treatment effect by differentiating control from treatment
groups or between groups of different disease states; and 5)
instrument responsiveness: ability of each instrument to detect
minimal clinically important changes within patients over time
(pre-and post-treatment phases) using distribution-based and
anchor-based approaches. Tests for statistical and clinical signif-
icances in score changes are discussed. For each of the ﬁve
approaches, suggested statistical methods and examples from the
literature are presented. CONCLUSIONS: The structured tax-
onomy developed in this study will help interpret clinical trial
results that use self-rated and interviewer-rated instruments, as
well as elucidate potential methods for developing and validat-
ing new instruments to assess the effectiveness of anxiolytic treat-
ments in trials.
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OBJECTIVES: Bipolar disorder, as well as some of the pharma-
cological agents used to treat it, often impairs patients’ ability to
function on a day-to-day basis. The goal of the present study was
to develop a sensitive, psychometrically sound self-report instru-
ment that would help to identify treatments effective in maxi-
mizing the functional status of bipolar patients. METHODS:
Through consultation with key opinion leaders, literature review,
and individual in-depth interviews with bipolar patients, the
team developed a questionnaire using 50 items to address the
following domains: cognitive functioning, sleep, role function-
ing, emotional functioning, energy/vitality, social functioning,
personal management, and sexual functioning. The draft ques-
tionnaire was then tested and revised through 2 iterative sets of
cognitive interviews with 19 additional patients in multiple loca-
tions. RESULTS: In general, the pretest participants deemed the
set of constructs addressed in the questionnaire to be both com-
prehensive and representative of their daily functioning. They
also reported that the ﬁnal set of items was easy to comprehend
and to ﬁll in, noting that the 7-point Likert-type response scale
seemed optimal; the points on the scale appeared to represent
the full spectrum of answer choices, yet participants could easily
distinguish between the options. Cognitive testing also resulted
in the elimination of 17 items, which were either deemed inessen-
tial to the measurement of functional status, applicable only to
a subset of patients (eg, family responsibilities), or too similar in
content to other items. CONCLUSIONS: The resulting ques-
tionnaire addresses all constructs considered central to the func-
tional status of patients with bipolar disorder, with 33 items that
are phrased to facilitate patient comprehension and completion.
A multisite, 600-patient validation study is currently under way
to evaluate the psychometric properties of this instrument.
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OBJECTIVES: The potential for antipsychotic-induced diabetes
is an important issue. Retrospective studies using large patient
databases have had conﬂicting ﬁndings regarding diabetes risks
associated with different antipsychotics. METHODS: Claims
data for thousands of psychosis patients treated or untreated
with antipsychotics were analyzed. Screening for preexisting dia-
betes, identiﬁcation of diabetes with prescription claims only,
and requirement of antipsychotic monotherapy provide better
control for confounding inﬂuences and represent a stronger
study design. Diabetes odds ratios for risperidone, olanzapine,
quetiapine, or conventional antipsychotics versus non-treatment
were estimated for all patients and for patients stratiﬁed by dose
levels. Logistic regression controlled for age, sex, type of 
psychosis, length of observation/treatment, preexisting excess
weight, and use of other drugs with diabetogenic effects.
RESULTS: Under a weaker study design, all of the antipsychotics
were associated with signiﬁcantly higher odds of diabetes rela-
tive to non-treatment. Odds ratios (95% conﬁdence intervals
[CI]) were: risperidone 1.388 (1.276–1.509), olanzapine 1.331
(1.224–1.446), quetiapine 1.394 (1.247–1.559), and conven-
tional antipsychotics 1.365 (1.238–1.503). Under a stronger
study design, relative odds for risperidone and quetiapine
declined, becoming statistically insigniﬁcant, whereas odds for
olanzapine and conventional antipsychotics increased. Odds
ratios (95% CI) were: risperidone 1.224 (0.962–1.562), olanza-
pine 1.858 (1.549–2.238), quetiapine 1.087 (0.742–1.612), and
conventional antipsychotics 1.755 (1.381–2.221). With quetiap-
ine, odds of diabetes were not signiﬁcantly increased at any dose
level relative to non-treatment. Odds were signiﬁcantly increased
